Health Catalyst, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $HCAT in the last 7 days.
No SEC Form 4 filings for $HCAT in the last 30 days.
See all $HCAT insider activity →Analysts downgraded five companies: Teradyne (TER) to Neutral with a $420 target, Ternium (TX) to Hold with a $55 target, Health Catalyst (HCAT) to Hold with a $1.8 target, DoubleVerify (DV) to Neutral with a $13.6 target, and Limbach (LMB) to Underweight with a $50 target. Stocks closed at $383.15, $54.21, $1.63, $13.31, and $42.75 respectively.
Bloomberg reported Anthropic’s preliminary Q2 revenue exceeded $11.5B, and CNBC said software firms face pressure that AI coding tools could reduce software spending. Shares of Health Catalyst (HCAT), GitLab (GTLB), Elastic (ESTC) and Marqeta (MQ) fell in afternoon trading. Health Catalyst guided Q3 revenue to $55.5M and cut 2026 revenue to $247.5M midpoint.
Health Catalyst (HCAT) reported Q2 2026 revenue of $70.5M, down 13% from $80.7M a year earlier. Technology revenue fell to $48.8M and professional services to $21.7M. The company completed the Vitalware divestiture for $147M cash and repaid about $160M of debt. FY2026 guidance: revenue $246M-$249M and adjusted EBITDA $18M-$18.5M.
Recent HCAT coverage spans earnings, corporate actions and financial news.
Negative sentiment from lower target.
The selloff is tied to deteriorating forward revenue expectations, not just the broader AI software narrative.
Divestiture and debt retirement improve balance-sheet optics, but migration-related churn and weaker professional services drive lower revenue; guidance narrows near-term outlook.
The guidance reset signals deteriorating demand and likely extends margin and growth pressure, driving a sharp repricing versus the prior outlook.
The deal is a balance-sheet and strategy reset: divest a non-core mid-revenue cycle unit, eliminate interest drag, and redirect capital toward its core healthcare intelligence and AI roadmap.
alphai scores every news story that mentions HCAT with an AI model for sentiment and relevance, and aggregates insider trades from Health Catalyst, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts downgraded five companies: Teradyne (TER) to Neutral with a $420 target, Ternium (TX) to Hold with a $55 target, Health Catalyst (HCAT) to Hold with a $1.8 target, DoubleVerify (DV) to Neutral with a $13.6 target, and Limbach (LMB) to Underweight with a $50 target. Stocks closed at $383.15, $54.21, $1.63, $13.31, and $42.75 respectively.
1 min readBloomberg reported Anthropic’s preliminary Q2 revenue exceeded $11.5B, and CNBC said software firms face pressure that AI coding tools could reduce software spending. Shares of Health Catalyst (HCAT), GitLab (GTLB), Elastic (ESTC) and Marqeta (MQ) fell in afternoon trading. Health Catalyst guided Q3 revenue to $55.5M and cut 2026 revenue to $247.5M midpoint.
7 min readHealth Catalyst (HCAT) reported Q2 2026 revenue of $70.5M, down 13% from $80.7M a year earlier. Technology revenue fell to $48.8M and professional services to $21.7M. The company completed the Vitalware divestiture for $147M cash and repaid about $160M of debt. FY2026 guidance: revenue $246M-$249M and adjusted EBITDA $18M-$18.5M.
6 min readHealth Catalyst (NASDAQ: HCAT) shares fell 23.1% after the company issued a weak Q3 revenue forecast and cut its full-year outlook. It expects Q3 revenue of $55.5 million versus $70.49 million in Q2, and reduced 2026 revenue guidance to $247.5 million at the midpoint. Q2 revenue met expectations, but the outlook pressured the stock.
4 min readHealth Catalyst, Inc. said it closed the July 31, 2026 sale of Vitalware, LLC to Med-Metrix, LLC. The divestiture generated $147M in total cash consideration, subject to adjustments. Health Catalyst plans to use proceeds and cash on hand to fully repay its credit facility, removing about $19M in annual GAAP interest expense, and to focus on its core healthcare intelligence and AI platform.
4 min readHealth Catalyst (NASDAQ:HCAT) reported Q2 CY2026 revenue of $70.49 million, down 12.7% year on year, but above analysts’ estimates by 2.1%. Non-GAAP EPS was $0.04, in line with consensus. Next-quarter revenue guidance was $55.5 million, 10.7% below estimates. The stock fell 25.5% to $1.71 after results.
6 min readHealth Catalyst, Inc. (HCAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Health Catalyst Reports Second Quarter 2026 Results SALT LAKE CITY, UT, August 6, 2026 — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported financ
6 min readHealth Catalyst (NASDAQ: HCAT) is set to report Q2 earnings Thursday after the bell. Last quarter, it reported revenue of $70.76M, down 10.9% YoY, and missed next-quarter guidance versus analysts. Consensus expects Q2 revenue to fall 14.6% YoY. HCAT stock is near $2.28 with an average analyst price target of $2.31.
3 min readHealth Catalyst (NASDAQ:HCAT) shareholders approved the board’s director slate and an advisory vote on named executive officer compensation, and ratified the auditor appointment, according to the company. A proposal to declassify the board and elect directors annually starting in 2029 failed, falling short of a 66.67% threshold. Voting results will be filed with the SEC.
3 min readHealth Catalyst, Inc. (HCAT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. hcat-20260716 FALSE 0001636422 0001636422 2026-07-16 2026-07-16 0001636422 dei:FormerAddressMember 2026-07-16 2026-07-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________ FORM 8-K ____________________
2 min read
